Culmination Bio

Culmination Bio is a data-centric biotech firm founded in 2022, built upon a foundational partnership with Intermountain Health that provides access to over 40 years of longitudinal, disease-agnostic patient data from 33 hospitals and 385 clinics. The company operates a 'Platform' business model, offering partners access to its proprietary data and analytics tools via its Apex Intelligence Platform to fuel discovery in diagnostics and therapeutics. As a private, likely pre-revenue entity, its strategy is to monetize this vast, clinically-linked dataset through collaborations, positioning itself as a key enabler of data-driven drug and diagnostic development in the genetics, genomics, and digital health sectors.

The Apex Intelligence Platform: a searchable platform organizing a 40+ year longitudinal data lake of de-identified patient records (clinical, -omics, claims, EMR) from Intermountain Health into customizable Discovery Cohorts, with linked access to over 9 million archival tissue samples.

Culmination competes with large real-world evidence providers (e.g., IQVIA, Flatiron Health), genomic databases (e.g., UK Biobank, All of Us), and biobanks. Its key differentiator is the 40-year longitudinal depth, the integration of multi-omics data with full clinical records, and the direct link to a vast archive of physical tissue samples from a single, integrated health system.